Ex-Gala­pa­gos med­ical chief heads to uniQure; Mar­tin Mack­ay lines up Rally­bio suc­ces­sor

→ For­mer Gala­pa­gos ex­ec Walid Abi-Saab has found a change in scenery, join­ing gene ther­a­py biotech uniQure as CMO. He left Shire in 2017 to be­come med­ical chief at Gala­pa­gos, whose part­ner­ship with Gilead on fil­go­tinib fell apart and is un­der­go­ing a re­build with CEO Paul Stof­fels. Abi-Saab an­nounced his re­tire­ment at Gala­pa­gos in De­cem­ber along­side CBO An­dré Hoeke­ma; CFO and COO Bart Fil­ius fol­lowed them out the door in ear­ly May. With Abi-Saab’s ap­point­ment, Ri­car­do Dol­metsch’s job ti­tle changes from R&D chief to pres­i­dent and CSO at uniQure, which re­leased Phase I/II da­ta for its Hunt­ing­ton’s gene ther­a­py AMT-130 that flum­moxed many ob­servers. Stifel’s Paul Mat­teis la­beled the da­ta drop “very con­fus­ing” as uniQure’s stock $QURE took a dive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER